Related Experiment Video
Updated: May 25, 2026

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
Therapeutics against influenza
Elena A Govorkova1, Jonathan A McCullers
1Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA. elena.govorkova@stjude.org
Abstract:
Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.
Insights
Influenza virus therapeutics have seen slow progress but accelerated recently. New antiviral strategies and host-pathogen interaction targets promise significant changes in influenza treatment.
Area of Science:
- Virology
- Infectious Diseases
- Immunology
Background:
- Influenza viruses remain significant global health threats despite extensive research.
- Therapeutic development for influenza has historically been slow but has accelerated in the last 20 years.
Purpose of the Study:
- To review the current state and future directions of influenza therapeutics.
- To highlight emerging strategies beyond traditional antiviral medications.
Main Methods:
- Review of existing and investigational antiviral medications for influenza.
- Exploration of novel therapeutic strategies targeting viral mechanisms and host responses.
Main Results:
- Current antiviral medications have limitations in scope and effectiveness.
- New antiviral compounds are in clinical development, and novel strategies are being explored.
Conclusions:
- Influenza therapy is poised for substantial evolution, driven by advancements in pathogenesis understanding and clinical validation.
- Future treatments may involve combination therapies, alternative delivery methods, and host-directed interventions.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Influenza
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Methods of reducing fever
Pharmacological Methods of Reducing Fever:

